Listar por autor "Weber, PEY."
Mostrando ítems 1-1 de 1
-
Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Rha, SY.; Wyrwicz, LS.; Weber, PEY.; Bai, Y.; Ryu, MH.; Lee, J.; Rivera, F.; Alves, GV.; Garrido, M. [Univ Mayor, Oncol, Santiago, Chile]; Shiu, KK.; González Fernández, M.; Li, J.; Lowery, M.; Cil, T.; Cruz, FJSM.; Qin, S.; Yin, L.; Bordia, S.; Bhagia, P.; Oh, DY (ELSEVIER, 2023-02)PD-1 inhibitors in combination with chemo have shown efficacy in G/GEJ cancer. We present results of the double-blind, placebo-controlled KEYNOTE-859 study of pembro + fluoropyrimidine- and platinum-containing chemo for ...